Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Basis of preparation

v3.23.1
Basis of preparation
12 Months Ended
Dec. 31, 2022
Basis of preparation.  
Basis of preparation

2.

Basis of preparation

Statement of Compliance

These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”).

Basis of Measurement and Presentation

These consolidated financial statements have been prepared using the historical cost convention except for financial instruments which have been measured at fair value. These consolidated financial statements were prepared on an accrual basis except for cash flow information.

These consolidated financial statements incorporate the financial statements of the Company and its 100% owned subsidiary. The accounts of the Company’s subsidiary are prepared for the same reporting period as the parent company, using consistent accounting policies. Inter-company transactions, balances and unrealized gains or losses on transactions are eliminated. The Company’s subsidiary is the following:

Name

    

Place of Incorporation

    

Ownership Percentage

 

XORTX Pharma Corp.

 

Canada

 

100

%

These consolidated financial statements were approved for issue by the Board of Directors on March 29, 2023.